Abstract: The use of interleukin-12 to prevent, to ameliorate, and to treat graft-versus-host disease in a mammal in need of such treatment is disclosed.
Type:
Grant
Filed:
January 21, 1994
Date of Patent:
November 12, 1996
Assignees:
Genetics Institute, Inc., The General Hospital Corporation
Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A.sub.2 /B enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.
Abstract: A novel method of screening for novel secreted mammalian proteins is described in which mammalian secretory leader sequences are detected using the yeast invertase gene as a reporter system.
Abstract: The invention provides novel DNA and peptide sequences encoding a family of phospholipase A.sub.2 enzymes, with specific activities of approximately 20 .mu.mol/min/mg in the mixed micelle assay. These enzymes are useful in methods for detecting the anti-inflammatory potential of various chemical agents. The invention also details novel methods for determining such potential using the novel sequences, methods for making the novel peptides, and methods for developing new anti-inflammatory drugs.
Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A.sub.2 /B enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.
Abstract: A novel homogeneous human cytokine, Natural Killer Stimulatory Factor, having the ability to induce the production of gamma interferon in vitro in human peripheral blood lymphocytes, and a pharmaceutical preparation containing it.
Type:
Grant
Filed:
September 18, 1990
Date of Patent:
October 10, 1995
Assignee:
Genetics Institute, Inc.
Inventors:
Giorgio Trinchieri, Bice Perussia, Michiko Kobayashi, Steven C. Clark, Gordon G. Wong, Rodney Hewick
Abstract: Methods of treating mammalian soft tissue injuries such as thermal and chemical burns, surgical incisions, ulcers, abrasions, skin grafts, and nervous tissue damage by administering a therapeutically effective amount of homogeneous K-fibroblast growth factor are provided. Also provided are methods of treating mammalian musculo-skeletal disorders such as bone grafts, bone fractures, ligament tears, cartilage tears, tendon tears, bursa inflammation and tendon inflammation by administering a therapeutically effective amount of homogeneous K-fibroblast growth factor. In accordance with the methods of the invention, homogeneous K-fibroblast growth factor may be administered to the mammal alone or in combination with other growth factors.
Type:
Grant
Filed:
June 12, 1992
Date of Patent:
July 4, 1995
Assignee:
Genetics Institute, Inc.
Inventors:
David T. Rogers, Neil M. Wolfman, Jasbir S. Seehra
Abstract: The invention described encompasses an isolated DNA sequence encoding all or a portion thereof of a cell surface receptor murine and human erythropoietin (hereinafter EPO-R), along with the isolated polypeptide expressed by the DNA sequence (i.e., isolated EPO-R). The invention also encompasses host cells containing the above-described DNA sequence, preferably, host cells which express the polypeptide encoded by the DNA sequence (EPO-R) at a significantly higher level than that produced by normal red blood cell precursors. The invention further encompasses DNA sequences encoding secreted forms of the human EPO-R and polypeptides corresponding thereto. The EPO-receptor in all of the disclosed forms can be used as models for designing drugs or in pharmaceutical compositions for treating anemias.
Type:
Grant
Filed:
June 10, 1993
Date of Patent:
January 3, 1995
Assignee:
Genetics Institute, Inc.
Inventors:
Alan D'Andrea, Gordon G. Wong, Simon S. Jones
Abstract: The-invention provides novel DNA and peptide sequences encoding a family of phospholipase A.sub.2 enzymes, with specific activities of approximately 20 .mu.mol/min/mg in the mixed micelle assay. These enzymes are useful in methods for detecting the anti-inflammatory potential of various chemical agents. The invention also details novel methods for determining such potential using the novel sequences, methods for making the novel peptides, and methods for developing new anti-inflammatory drugs.
Abstract: A method for purifying erythropoietin is described. The method comprises treating partially purifying erythropoietin by reverse phase high performance liquid chromatography to obtain homogeneous erythropoietin having a molecular weight of about 34,000 daltons on SDS PAGE and moving a single peak on reverse phase HPLC. The homogeneous erythropoietin protein preferably has a specific activity of at least 120,000 IU, more preferably at least 160,000 IU per absorbance unit at 280 nm.
Abstract: A reverse-phase HPLC method is disclosed which allows the separation of DPU and PTH-Trp and, therefore, the correct assignment of tryptophan residues in an amino acid sequence. The method is based on a modification of the conventional HPLC gradient commonly used to elute and separate all PTH amino acids of interest in automated and manual sequencing. In one embodiment, using automated instruments manufactured by Applied Biosystems, gradient modification is achieved by changing the manufacturer-supplied gradient program which controls the operation of the HPLC pumps in the instrument. Using the methods of the present invention, the correct and reliable assignment of tryptophan residues is possible and was reproducible over time, even with small sample sizes.